Walleye Trading’s Sutro Biopharma STRO Stock Holding History

Walleye Trading’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,126	Closed	-$319K	–	5271
2018 Q3	$319K	Buy	+2,126	New	+$321K	﹤0.01%	3351

Other funds holding STRO

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Walleye Trading's STRO Position: Q4 2018 in Review

Walleye Trading sold out of Sutro Biopharma (STRO) in Q4 2018, closing a stake of 2,126 shares — an estimated $319K sold.

Walleye Trading first reported a position in STRO in Q3 2018 and held it in 1 quarter. The position peaked at $319K in Q3 2018. 43 funds tracked by Wall St. Rank hold STRO as of Q4 2018.

Walleye Trading reported no remaining Sutro Biopharma position as of Q4 2018 after selling out during the quarter.
Walleye Trading sold 2,126 Sutro Biopharma shares in Q4 2018, an estimated $319K.
Walleye Trading first reported a position in Sutro Biopharma in Q3 2018 and held it in 1 quarter.
Walleye Trading's Sutro Biopharma position peaked at $319K in Q3 2018.
43 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2018.

Based on Walleye Trading's 13F filing for Q4 2018, filed 14 Feb 2019.